The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies. Cancer stem cells (CSCs), which are not targeted by current therapies, may be the reason for pronounced therapy resistance. A new treatment option in phase II trials is cabozantinib that inhibits the pancreatic CSC surfac...

詳細記述

保存先:
書誌詳細
主要な著者: Hage, C, Rausch, V, Giese, N, Giese, T, Schönsiegel, F, Labsch, S, Nwaeburu, C, Mattern, J, Gladkich, J, Herr, I
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2013
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674365/
https://ncbi.nlm.nih.gov/pubmed/23661005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2013.158
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料